Wire · opportunities
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
A Phase 1 study of an investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated non-small cell lung cancer (NSCLC) supported the selection of a 2.5 mg/kg dose for the upcoming global Phase 3 IZABRIGHT-Lung01 trial, showing a 33.3% objective response rate and manageable safety.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must prepare for increased competition in EGFR-mutated lung cancer therapies as a new antibody-drug conjugate clears Phase 1 safety and efficacy hurdles and moves into Phase 3 testing in South Korea. This advance opens regulatory doors but demands rapid clinical and commercial strategy adjustments.
◆ Coverage
1 source · 12 Sep 2026
◆ Related on Wire
◆ Topics